While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...
Clinical Trials Arena on MSN
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics will still submit tovecimig for approval despite the OS miss.
Compass Pathways may be the first to benefit from an accelerated approval process.
The Consumer Policy Center estimated that Compass’ market share was up to 40 percent after its deal for Anywhere Real Estate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results